# NCT06520345 (NCT06520345)

> The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06520345
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
- Conditions: Metastatic Castration-resistant Prostate Cancer
- Interventions: 177Lu-TLX591; Enzalutamide; Abiraterone; Docetaxel
- Enrollment: 520
- Primary outcome: Radiographic Progression-free Survival

## Commentary we found

- X threads: 9
- YouTube: 7
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct06520345

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06520345", "email": "<work email>"}; the inbox owner confirms by the emailed link.